ASH 2023 | Impact of pre-treatment features & choice of therapy on outcomes of older adults with AML

Uma Borate, MD, The Ohio State University, Columbus, OH, outlines the findings of an analysis from the Beat AML master trial (NCT03013998), in which patients over the age of 60 with acute myeloid leukemia (AML) underwent complete genomic sequencing and were assigned to a sub-study based on their cytogenetics. A large subset of patients were not eligible for enrollment into a sub-study and instead were followed for off-study treatment. These patients received various standard-of-care regimens, including venetoclax + hypomethylating agent (V/HMA), any form of intensive chemotherapy (IC), alternative non-intensive therapy (NIT), or no therapy. The survival outcomes of these patients were impacted less by the therapy approach used than by pre-treatment clinical features such as age, performance status, cytogenetics, and other disease factors. Therefore, Dr Borate highlights the complexity of AML treatment and emphasizes the need to select an appropriate therapeutic option based on the unique characteristics of each patient. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.